藥物代謝和藥物相互作用體外研究試劑
|
Product Summary
|
|
|
1) CYPxxxR Bactosomes (human) 人細胞色素cytochrome P450 (CYP)
|
|
|
Human CYP co-expressed with human NADPH-CYP reductase in E. coli
|
|
|
Enzyme
|
Product Description
|
|
CYP1A1
|
CYP1A1R Bactosomes
|
|
CYP1A1LR Bactosomes
|
|
|
CYP1A2
|
CYP1A2R Bactosomes
|
|
CYP1A2LR Bactosomes
|
|
|
CYP1B1.1
|
CYP1B1LR Bactosomes
|
|
CYP1B1.3
|
CYP1B1*3LR Bactosomes
|
|
CYP1B1.4
|
CYP1B1*4LR Bactosomes
|
|
CYP2A6
|
CYP2A6R Bactosomes
|
|
CYP2A13
|
CYP2A13LR Bactosomes
|
|
CYP2A13R Bactosomes
|
|
|
CYP2B6
|
CYP2B6BR Bactosomes
|
|
CYP2B6R Bactosomes
|
|
|
CYP2B6LR Bactosomes
|
|
|
CYP2C8
|
CYP2C8BR Bactosomes
|
|
CYP2C8BLR Bactosomes
|
|
|
CYP2C8R Bactosomes
|
|
|
CYP2C8LR Bactosomes
|
|
|
CYP2C9.1
|
CYP2C9BHR Bactosomes
|
|
CYP2C9BR Bactosomes
|
|
|
CYP2C9HR Bactosomes
|
|
|
CYP2C9R Bactosomes
|
|
|
CYP2C9.2
|
CYP2C9*2BR Bactosomes
|
|
CYP2C9*2R Bactosomes
|
|
|
CYP2C9.3
|
CYP2C9*3BR Bactosomes
|
|
CYP2C9*3R Bactosomes
|
|
|
CYP2C18
|
CYP2C18LR Bactosomes
|
|
CYP2C19
|
CYP2C19R Bactosomes
|
|
CYP2C19LR Bactosomes
|
|
|
CYP2D6.1
|
CYP2D6R Bactosomes
|
|
CYP2D6LR Bactosomes
|
|
|
CYP2D6.2
|
CYP2D6*2R Bactosomes
|
|
CYP2D6.10
|
CYP2D6*10R Bactosomes
|
|
CYP2D6.39
|
CYP2D6*39R Bactosomes
|
|
CYP2E1
|
CYP2E1BR Bactosomes
|
|
CYP2E1R Bactosomes
|
|
|
CYP2J2
|
CYP2J2LR Bactosomes
|
|
CYP3A4
|
CYP3A4BR Bactosomes
|
|
CYP3A4BLR Bactosomes
|
|
|
CYP3A4R Bactosomes
|
|
|
CYP3A4LR Bactosomes
|
|
|
CYP3A5
|
CYP3A5BR Bactosomes
|
|
CYP3A5BLR Bactosomes
|
|
|
CYP3A5R Bactosomes
|
|
|
CYP3A5LR Bactosomes
|
|
|
CYP4A11
|
CYP4A11BR Bactosomes
|
|
CYP4A11R Bactosomes
|
|
|
CYP4A11LR Bactosomes
|
|
|
CYP4F2
|
CYP4F2BLR Bactosomes
|
|
All the above products are supplied at 1 nmol CYP per vial.
|
|
|
2) CYPxxxR Easy CYP Bactosomes (human) 人細胞色素
|
|
|
Human CYP co-expressed with human NADPH-CYP reductase in E. coli
|
|
|
Enzyme
|
Product Description
|
|
CYP1A1
|
CYP1A1R EasyCYP Bactosomes
|
|
CYP1A1LR EasyCYP Bactosomes
|
|
|
CYP1A2
|
CYP1A2R EasyCYP Bactosomes
|
|
CYP1A2LR EasyCYP Bactosomes
|
|
|
CYP1B1.1
|
CYP1B1LR EasyCYP Bactosomes
|
|
CYP1B1.3
|
CYP1B1*3LR EasyCYP Bactosomes
|
|
CYP2A6
|
CYP2A6R EasyCYP Bactosomes
|
|
CYP2A13
|
CYP2A13R EasyCYP Bactosomes
|
|
CYP2A13LR EasyCYP Bactosomes
|
|
|
CYP2B6
|
CYP2B6BR EasyCYP Bactosomes
|
|
CYP2B6R EasyCYP Bactosomes
|
|
|
CYP2B6LR EasyCYP Bactosomes
|
|
|
CYP2C8
|
CYP2C8BR EasyCYP Bactosomes
|
|
CYP2C8BLR EasyCYP Bactosomes
|
|
|
CYP2C8R EasyCYP Bactosomes
|
|
|
CYP2C8LR EasyCYP Bactosomes
|
|
|
CYP2C9.1
|
CYP2C9BHR EasyCYP Bactosomes
|
|
CYP2C9BR EasyCYP Bactosomes
|
|
|
CYP2C9HR EasyCYP Bactosomes
|
|
|
CYP2C9R EasyCYP Bactosomes
|
|
|
CYP2C9.2
|
CYP2C9*2BR EasyCYP Bactosomes
|
|
CYP2C9*2R EasyCYP Bactosomes
|
|
|
CYP2C9.3
|
CYP2C9*3BR EasyCYP Bactosomes
|
|
CYP2C9*3R EasyCYP Bactosomes
|
|
|
CYP2C18
|
CYP2C18LR EasyCYP Bactosomes
|
|
CYP2C19
|
CYP2C19R EasyCYP Bactosomes
|
|
CYP2C19LR EasyCYP Bactosomes
|
|
|
CYP2D6.1
|
CYP2D6R EasyCYP Bactosomes
|
|
CYP2D6LR EasyCYP Bactosomes
|
|
|
CYP2D6.2
|
CYP2D6*2R EasyCYP Bactosomes
|
|
CYP2D6.10
|
CYP2D6*10R EasyCYP Bactosomes
|
|
CYP2D6.39
|
CYP2D6*39R EasyCYP Bactosomes
|
|
CYP2E1
|
CYP2E1BR EasyCYP Bactosomes
|
|
CYP2E1R EasyCYP Bactosomes
|
|
|
CYP2J2
|
CYP2J2LR EasyCYP Bactosomes
|
|
CYP3A4
|
CYP3A4BR EasyCYP Bactosomes
|
|
CYP3A4BLR EasyCYP Bactosomes
|
|
|
CYP3A4R EasyCYP Bactosomes
|
|
|
CYP3A4LR EasyCYP Bactosomes
|
|
|
CYP3A5
|
CYP3A5BR EasyCYP Bactosomes
|
|
CYP3A5BLR EasyCYP Bactosomes
|
|
|
CYP3A5R EasyCYP Bactosomes
|
|
|
CYP3A5LR EasyCYP Bactosomes
|
|
|
CYP4A11
|
CYP4A11BR EasyCYP Bactosomes
|
|
CYP4A11R EasyCYP Bactosomes
|
|
|
CYP4A11LR EasyCYP Bactosomes
|
|
|
CYP4F2
|
CYP4F2BLR EasyCYP Bactosomes
|
|
EasyCYP Bactosomes are prepared to a standard specification:
|
|
|
1 nmol CYP per ml; 10 mg total protein per ml; 0.5 nmol CYP per vial
|
|
|
3) Bactosome kits
|
|
|
Product Description
|
Contents
|
|
Low Reductase Bactosome Kit
|
1 vial of each of the following Bactosomes:
CYP1A2LR (CYP012); CYP2C9R (CYP006); CYP2C19LR (CYP028); CYP2D6LR (CYP013); CYP3A4LR (CYP010); Control (CYP003) |
|
High Reductase Bactosome Kit
|
1 vial of each of the following Bactosomes:
CYP1A2R (CYP001); CYP2C9HR (CYP019) CYP2C19R (CYP008); CYP2D6R (CYP007) CYP3A4R (CYP002); Control (CYP003) |
|
4) CYPxxxR Bactosomes (dog)
|
|
|
Dog CYP co-expressed with dog NADPH-CYP reductase in E. coli
|
|
|
Enzyme
|
Product Description
|
|
CYP1A1
|
Dog CYP1A1LR Bactosomes
|
|
CYP1A2
|
Dog CYP1A2LR Bactosomes
|
|
CYP2B11
|
Dog CYP2B11LR Bactosomes
|
|
CYP2C21
|
Dog CYP2C21LR Bactosomes
|
|
CYP2C41
|
Dog CYP2C41LR Bactosomes
|
|
CYP2D15
|
Dog CYP2D15LR Bactosomes
|
|
CYP3A12
|
Dog CYP3A12LR Bactosomes
|
|
CYP3A26
|
Dog CYP3A26LR Bactosomes
|
|
All the above products are supplied at 1 nmol CYP per vial.
|
|
|
5) Control preparations
|
|
|
Product Description
|
Size
|
|
Control Bactosomes
|
10 mg protein
|
|
Control EasyCYP Bactosomes
|
5 mg protein
|
|
Reductase Bactosomes
|
4 nmol reductase
|
|
Control cytosol
|
1 mg protein
|
|
Control EasyCYP Bactosomes are supplied at a standard protein concentration of 10 mg per ml.
|
|
|
Control cytosol is supplied at a standard protein concentration of 10 mg per ml.
|
|
|
6) Other enzymes
|
|
|
Product Description
|
Size
|
|
Human SULT1A1*1
|
1 mg cytosolic
|
|
Human SULT1A1*2
|
1 mg cytosolic
|
|
Human SULT1A2
|
1 mg cytosolic
|
|
Human SULT1A3
|
1 mg cytosolic
|
|
Human SULT1B1
|
1 mg cytosolic
|
|
Human SULT1C2
|
1 mg cytosolic
|
|
Human SULT1C4
|
1 mg cytosolic
|
|
Human SULT1E1
|
1 mg cytosolic
|
|
Human SULT2A1
|
1 mg cytosolic
|
|
Human GSTA1
|
1 mg cytosolic
|
|
Human GSTM1
|
1 mg cytosolic
|
|
Human aldehydeoxidase
|
250 μl cytosoli
|
|
Human aldehydedehydrogenase 1A1
|
1 mg cytosolic
|
|
Human carboxylesterase 1 (CES1)
|
1 mg membran
|
|
Human carboxylesterase 2 (CES2)
|
1 mg membran
|
|
Human UGT1A6 Bactosomes
|
5 mg membran
|
|
7) Antibodies (other than Nosan antibodies)
|
|
|
Product Description
|
Size
|
|
Pre-immune sheep serum
|
50 μl
|
|
Polyclonal sheep anti-rat UGT antiserum
|
50 μl
|
|
Polyclonal sheep anti-human SULT1A3 antiserum
|
50 μl
|
| 8) Chemicals | ||
| Product Description | Size | |
| 4’-hydroxydiclofenac, > 98% | 0.1 mg | CYP2C9 metabolite of diclofenac |
| 5 mg | ||
| 6α-hydroxypaclitaxel, > 97% | 0.1 mg | CYP2C8 metabolite of paclitaxel |
| 5 mg | ||
| [1-14C] lauric acid, > 98%, 49.4 mCi/mmol | 1.85 MBq(50 μCi) | Substrate for CYP2E1 and CYP4A11. |
| [1-14C] 11-hydroxylauric acid, > 98%, 51.8 mCi/mmol | 1.85 MBq(50 μCi) | CYP2E1 metabolite of lauric acid (minor metabolite of CYP4A11). |
| [1-14C] 12-hydroxylauric acid, > 98%, 50.8 mCi/mmol | 1.85 MBq | CYP4A11 metabolite of lauric acid. |
| Tolbutamide, > 98% | 100 mg | Substrate for CYP2C. |
| Hydroxytolbutamide, > 98% | 10 mg | CYP2C metabolite of tolbutamide. |
| Carboxytolbutamide, > 98% | 10 mg | Metabolite of tolbutamide. |
| Carboxytolbutamide methyl ester, > 98% | 10 mg | Derivative of carboxytolbutamide, a metabolite of tolbutamide. |
| Tolbutamide kit (containsTolbutamide Hydroxytolbutamide Carboxytolbutamide Carboxytolbutamide methyl ester), > 98% | 100 mg of tolbutamide, 10 mg each of metabolites. | Tolbutamide Hydroxytolbutamide Carboxytolbutamide >Carboxytolbutamide methyl ester |
| 7-ethoxyresorufin, > 98% | 10 mg | Substrate for CYP1A1, CYP1A2 and CYP1B1. |
| Resorufin, > 98% | 100 mg | CYP1A1, CYP1A2 and CYP1B1 metabolite of 7-ethoxyresorufin. |
| 7-benzyloxyquinoline (7BQ), > 98% | 10 mg | Substrate for CYP3A4. |
| 7-hydroxyquinoline (7HQ), > 98% | 10 mg | Metabolite of 7-BQ. |
| [3-14C] 7-ethoxycoumarin, 46.0 mCi/mmol, > 99% | 1.85 MBq (50 μCi) | CYP substrate |
| MAMC, > 98% | 10 mg | Substrate for CYP2D6. |
| 25 mg | ||
| HAMC, > 98% | 10 mg | CYP2D6 metabolite of MAMC. |
| 7-methoxy-4-(trifluoromethyl)-coumarin (MFC), > 98% | 10 mg | Substrate for CYP2C9. |
| 25 mg | ||
| 7-benzyloxy-4-(trifluoromethyl)-coumarin (BFC), > 98% | 10 mg | Substrate for CYP3A4. |
| 25 mg | ||
| 7-hydroxy-4-(trifluoromethyl)-coumarin (HFC), > 98% | 10 mg | Metabolite of MFC and BFC. |
| Omeprazole, > 98% | 1 g | Substrate of CYP2C19. |
| 3-O-methylfluorescein, > 98% | 10 mg | Substrate of CYP1A1 and CYP2C19. |
| 25 mg | ||
| Tienilic acid, > 98% | 10 mg | Mechanism-based inhibitor of CYP2C9. |
| 25 mg | ||
| Paclitaxel, > 98% | 25 mg | Substrate of CYP2C8. |
| 100 mg | ||
| Ketoconazole, > 98% | 100 mg | CYP3A4 inhibitor. |
| 1 g | ||
| Diclofenac, > 98% | 10 g | Substrate of CYP2C9 and CYP2C18. |
| Amodiaquine dihydrochloride dihydrate, > 98% | 5 g | Substrate of CYP2C8. |
| Desethylamodiaquine, > 98% | 10 mg | CYP2C8 metabolite of amodiaquine. |
| 25 mg | ||
| Terfenadine, > 98% | 5 g | Substrate of CYP3A4 and CYP2J2 |
| (-)-N-3-benzylphenobarbital, > 98% | 10 mg | Specific inhibitor of CYP2C19. |
| 25 mg | ||
| Montelukast sodium | 10 mg | Inhibitor of CYP2C8. |
| 25 mg | ||
 |
 |
 |
| 官網：m.baichuan365.com | 微信服務號：iseebio | 微博：seebiobiotech |
 |
 |
 |
| 商城：mall.seebio.cn | 微信訂閱號：seebiotech | 泉養堂：www.canmedo.com |
下一篇：LUDOX 硅溶膠上一篇： 穩定同位素試劑，氘、氧十八
相關資訊
- α-乳白蛋白
- Seebio實驗室儀器、耗材促銷
- 西寶生物2019年端午放假及工作安排
- ACS Nano：突破！科學家利用來自尿液的生物標志物進行早期癌癥篩查
- 酶穩定劑和蛋白保護劑
- Nature：細胞圖譜揭示免疫系統抗擊癌癥新細節
- 中國蛋白質組學世界領先
- 飲食中反式脂肪酸使人健忘
- Cancer Res：科學家們在胰腺癌中發現了“抑癌細胞”
- Cell子刊：給CAR-T細胞標記上成像示蹤劑，可在體內實時追蹤CAR-T細胞
新進產品
同類文章排行
- 膽堿酯酶檢測原料一覽
- 猴痘病毒檢測原料（涵蓋診斷酶、抗原、抗體），西寶生物助力猴痘檢測
- 西寶生物CHO細胞、HEK293細胞、 Vero細胞培養基產品
- 人和動物免疫球蛋白IgG全新上市
- 如何選擇合適的表面活性劑？
- 尿液分析試紙檢測原理及產品推薦
- 總膽紅素/直接膽紅素檢測一站式解決方案
- 分子診斷用酶原料一站式服務盡在西寶生物
- 體外診斷中交聯劑的用途與選擇
- 優異的化妝品級水溶性β-1,3-葡聚糖
資訊文章
您的瀏覽歷史
